SLC5A2 and hydrops fetalis: SGLT-2 inhibitors reduced the risk of a composite of hospitalization for HF and CV death (HR [95 % CI] = 0.78 [0.70, 0.87], Pfix < 0.001; heterogeneity, P = 0.46, I2 = 0 %) and the risk of hospitalization for HF (OR [95 % CI] = 0.71 [0.61, 0.83], Pfix < 0.001; heterogeneity, P = 0.99, I2 = 0 %).